High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

Oncology - Switzerland
doi 10.1159/000084823
Full Text
Abstract

Available in full text

Date
Authors
Publisher

S. Karger AG

Related search

Weekly Docetaxel in the Treatment of Metastatic Breast Cancer

Therapeutics and Clinical Risk Management
2008English

Capecitabine in Combination With Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: An Observational Study

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2016English

Pembrolizumab as First-Line Treatment for Metastatic Uveal Melanoma

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Outcome of Eribulin as a Late Treatment Line for Thai Metastatic Breast Cancer Patients

OncoTargets and Therapy
OncologyPharmacology
2018English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients

Cancers
Cancer ResearchOncology
2019English

First-Line Treatment of Metastatic Lung Cancer—New Developments

Oncology & Hematology Review (US)
2008English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Breast Care
SurgeryOncology
2011English

Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression as First-Line Chemotherapy in Patients With HER2+ Metastatic Breast Cancer: HERTAX Trial

Clinical Breast Cancer
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy